News & Information

Learn how MSK researchers are deploying mRNA vaccines against pancreatic cancer.

African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.

A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2–6 in Chicago.

The Marie-Josée Kravis Center for Cancer Immunobiology (CCI), made possible by a generous $40 million gift from Henry R. Kravis to honor the visionary leadership of his wife, Marie-Josée Kravis, will establish a strategic research infrastructure that will seamlessly unite MSK scientists and physicians to further accelerate immunotherapy treatments for people with cancer.

Since 2019, the Robbins Family Foundation has sponsored awards to honor MSK nurses’ extraordinary achievements and contributions to MSK’s mission and core values.

Rather than promoting genetic chaos, loss of p53 leads to an orderly progression of genetic changes that no one saw coming.

Researchers learn how prostate cancer cells change their type to survive treatment.

Learn why MSK researchers developed MACHETE, a new CRISPR-based technique to study large-scale genetic deletions efficiently in laboratory models.

Symantha Wilson was crushed when chemotherapy quit fighting her lymphoma — and thrilled when immuno¬therapy beat back the cancer. But why doesn’t immunotherapy help more people? MSK researchers are finding answers.

This new era of cancer research investigates how the disease in certain locations interacts with all the body’s systems. Focusing on cancer’s ecosystem promises to reveal lifesaving insights, especially into metastasis.

To help some patients to overcome leukemia, MSK doctors are calling upon patients’ microbiomes — the vast ecosystems of microorganisms that live within us, especially the gut. These microbes appear to help some patients recover from bone marrow and stem cell transplants.

Learn how a heralded clinical trial at Memorial Sloan Kettering Cancer Center is being expanded that made rectal cancer disappear in every participant using only immunotherapy that targets a rare mutation — without the need for surgery, chemotherapy, or radiation.

MSK-led research could change the practice of medicine for millions of people whose breast cancer has spread. Research led by Dr. Shanu Modi has demonstrated that a targeted drug called trastuzumab deruxtecan blocks the protein HER2 even when its levels are low — the case for about 55% of people with breast cancer.

The protein made by the p53 gene helps guard the body against cancer, in part by detecting and repairing damaged DNA. Over the 30 years since p53 was first discovered, it has remained a stubborn mystery, resisting efforts to tease apart exactly how the loss of the gene’s protection leads to the development of cancer. In August 2022, researchers in the Sloan Kettering Institute were able to provide some new answers that hint at new avenues for treatment.